The past two decades have heralded dramatic improvements in outcomes for people living with heart failure with reduced ejection fraction (HFrEF).1 The more widespread implementation of disease modifying pharmacological therapies,2 supported by landmark trials of renin-angiotensin system inhibitors3 and ...
On the medication front, there are now "four pillars of survival" in the setting ofheart failurewith reduced ejection fraction (EF), a cardiologist told a gathering of hospitalists. The quartet of drugs are beta blockers, angiotensin receptor–neprilysin inhibitors, mineralocorticoid receptor antagon...
Introduction: European, American and UK guidelines all endorse the prescription of the 'four pillars' of treatment (ACE/ARBs, b-blockers, MRAs and SGLT2 inhibitors) for heart failure with reduced LV systolic function (HFrEF). Many doctors believe that it is difficult to initiate and maintain ...
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapydoi:10.1002/ehf2.15095Cardiac remodellingHeart failureMedical therapyCardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF)...
Methods: This prospective, single center, observational study included consecutive in-hospital patients with HFrEF. After performing propensity score matching, they were divided according to treatment strategy into group 1 (G1), with predischarge start of all four-pillars, with their up-titration ...